Pliant Therapeutics (PLRX) Retained Earnings (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Retained Earnings of -$879.4 million for Q1 2026, down 553204.4% year-over-year from N/an in Q1 2025, and down 5862806.67% quarter-over-quarter from -$15000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Retained Earnings (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Retained Earnings for 8 consecutive years, with -$879.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 553204.4% year-over-year to -$879.4 million; the TTM figure through Mar 2026 stood at -$879.4 million (down 553204.4% YoY), while the FY2025 annual figure was -$15000.0, down 104.67% from the prior year.
- Retained Earnings eased to -$879.4 million in Q1 2026 per PLRX's latest filing, from -$15000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $848000.0 in Q3 2024 and bottomed at -$879.4 million in Q1 2026.
- Historically, Retained Earnings has averaged -$210.0 million across 5 years, with a median of -$1.3 million in 2023.
- Annual changes were most pronounced in 2024 — Retained Earnings soared 144.47% — and 2026, when it sank 553204.4%.
- Pliant Therapeutics' Retained Earnings stood at -$338.4 million in 2022, then soared by 100.1% to $345000.0 in 2023, then fell by 6.96% to $321000.0 in 2024, then slumped by 104.67% to -$15000.0 in 2025, then sank by 5862806.67% to -$879.4 million in 2026.
- Business Quant data shows PLRX's Retained Earnings at -$879.4 million in Q1 2026, -$15000.0 in Q4 2025, and $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | -901.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -901.81 Mn |
| Mar 31, 2026 | -879.44 Mn |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | -809.52 Mn |
| Mar 31, 2025 | 159,000.00 |
| Dec 31, 2024 | 321,000.00 |
| Sep 30, 2024 | 848,000.00 |
| Jun 30, 2024 | -617,000.00 |
| Mar 31, 2024 | -546.70 Mn |
| Dec 31, 2023 | 345,000.00 |
| Sep 30, 2023 | -1.91 Mn |
| Jun 30, 2023 | -417.15 Mn |
| Mar 31, 2023 | -1.33 Mn |
| Dec 31, 2022 | -338.41 Mn |
| Sep 30, 2022 | -303.35 Mn |
| Jun 30, 2022 | -272.74 Mn |
| Mar 31, 2022 | -950,000.00 |
| Dec 31, 2021 | -215.09 Mn |
| Sep 30, 2021 | -190.56 Mn |